Anbio Biotechnology Class A Ordinary Shares
Support and Resistance Levels
Past performance
News About NNNN
All events for NNNN
All deals for NNNN
Financial Ratios
Financial Statements
NNNN vs Sector & Peers
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings. Website anbio.com
Headquarters Frankfurt am Main, HE, DE